Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Myeloid 2Other hematologic neoplasm 1

Conditions

Thrombocythemia, Essential 2Primary Myelofibrosis 2Polycythemia Vera 2Myeloproliferative Disorders 1Hematologic Neoplasms 1

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × LY2784544 × Clear all
NCT01594723 2025-07-23

A Study of LY2784544 in Participants With Myeloproliferative Neoplasms

Eli Lilly and Company

Phase 2 Active not recruiting
110 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

NCT01134120 2018-04-17

A Study in Myeloproliferative Disorders

Eli Lilly and Company

Phase 1 Completed
80 enrolled
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT01520220 2017-04-12

Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms

Eli Lilly and Company

Phase 1 Completed
100 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡